Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study
Purpose Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusi...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2022-05, Vol.157 (3), p.551-559 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 3 |
| container_start_page | 551 |
| container_title | Journal of neuro-oncology |
| container_volume | 157 |
| creator | Mo, F. Meletti, S. Belcastro, V. Quadri, S. Napolitano, M. Bello, L. Dainese, F. Scarpelli, M. Florindo, I. Mascia, A. Pauletto, G. Bruno, F. Pellerino, A. Giovannini, G. Polosa, M. Sessa, M. Conti Nibali, M. Di Gennaro, G. Gigli, G. L. Pisanello, A. Cavallieri, F. Rudà, R. |
| description | Purpose
Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients.
Methods
We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).
Results
Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice.
In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI).
Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months.
Side effects were mainly mild (grade 1–2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence.
Conclusions
This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions. |
| doi_str_mv | 10.1007/s11060-022-03998-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2649256882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2649256882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-4433d3c06aa6b9239f39335e7b1022e7b343002aec8ee24657e4a5a5e4fd29fe3</originalsourceid><addsrcrecordid>eNp9kUuLFTEQhYMoznX0D7iQgJtxEU1SeXTc6TDqwAVBRnAXcrurtYfuTpukhf735npHBReuTh5fnariEPJU8JeCc_sqC8ENZ1xKxsG5hpl7ZCe0BWbBwn2y48JYpp36ckYe5XzLOVcWxENyBhqctdrtyLYPbcxhGjqkw0ynOMfyDVNYtuP17c2nK3pxSKGeyzrFxBKOoWBHcRlGXPL24jVNmNexZNqnONEw0-sSxqHqVF-HFueCqTIlxbxgW4YfSHNZu-0xedCHMeOTOz0nn99d3Vx-YPuP768v3-xZqxwvTCmADlpuQjAHJ8H14AA02oOoi1cBBZzLgG2DKJXRFlXQQaPqO-l6hHNycfJdUvy-Yi5-GnKL4xhmjGv20igntWkaWdHn_6C3cU1zna5S2jUVE0dKnqi2rpQT9n5JwxTS5gX3x2D8KRhf5_O_gvGmFj27s14PE3Z_Sn4nUQE4Abl-zV8x_e39H9ufAdiZzA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2659825612</pqid></control><display><type>article</type><title>Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Mo, F. ; Meletti, S. ; Belcastro, V. ; Quadri, S. ; Napolitano, M. ; Bello, L. ; Dainese, F. ; Scarpelli, M. ; Florindo, I. ; Mascia, A. ; Pauletto, G. ; Bruno, F. ; Pellerino, A. ; Giovannini, G. ; Polosa, M. ; Sessa, M. ; Conti Nibali, M. ; Di Gennaro, G. ; Gigli, G. L. ; Pisanello, A. ; Cavallieri, F. ; Rudà, R.</creator><creatorcontrib>Mo, F. ; Meletti, S. ; Belcastro, V. ; Quadri, S. ; Napolitano, M. ; Bello, L. ; Dainese, F. ; Scarpelli, M. ; Florindo, I. ; Mascia, A. ; Pauletto, G. ; Bruno, F. ; Pellerino, A. ; Giovannini, G. ; Polosa, M. ; Sessa, M. ; Conti Nibali, M. ; Di Gennaro, G. ; Gigli, G. L. ; Pisanello, A. ; Cavallieri, F. ; Rudà, R.</creatorcontrib><description>Purpose
Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients.
Methods
We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).
Results
Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice.
In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI).
Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months.
Side effects were mainly mild (grade 1–2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence.
Conclusions
This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-022-03998-6</identifier><identifier>PMID: 35397759</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acetamides ; Anticonvulsants - therapeutic use ; Brain cancer ; Brain Neoplasms - complications ; Brain Neoplasms - drug therapy ; Brain tumors ; Clinical Study ; Cognition ; Convulsions & seizures ; Drug-Related Side Effects and Adverse Reactions ; Epilepsies, Partial - complications ; Epilepsies, Partial - drug therapy ; Epilepsy ; Epilepsy - complications ; Epilepsy - etiology ; Humans ; Lacosamide - therapeutic use ; Magnetic resonance imaging ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Neurology ; Oncology ; Patients ; Quality of Life ; Retrospective Studies ; Seizures ; Seizures - drug therapy ; Side effects ; Treatment Outcome</subject><ispartof>Journal of neuro-oncology, 2022-05, Vol.157 (3), p.551-559</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-4433d3c06aa6b9239f39335e7b1022e7b343002aec8ee24657e4a5a5e4fd29fe3</citedby><cites>FETCH-LOGICAL-c490t-4433d3c06aa6b9239f39335e7b1022e7b343002aec8ee24657e4a5a5e4fd29fe3</cites><orcidid>0000-0002-8469-7567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-022-03998-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-022-03998-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35397759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mo, F.</creatorcontrib><creatorcontrib>Meletti, S.</creatorcontrib><creatorcontrib>Belcastro, V.</creatorcontrib><creatorcontrib>Quadri, S.</creatorcontrib><creatorcontrib>Napolitano, M.</creatorcontrib><creatorcontrib>Bello, L.</creatorcontrib><creatorcontrib>Dainese, F.</creatorcontrib><creatorcontrib>Scarpelli, M.</creatorcontrib><creatorcontrib>Florindo, I.</creatorcontrib><creatorcontrib>Mascia, A.</creatorcontrib><creatorcontrib>Pauletto, G.</creatorcontrib><creatorcontrib>Bruno, F.</creatorcontrib><creatorcontrib>Pellerino, A.</creatorcontrib><creatorcontrib>Giovannini, G.</creatorcontrib><creatorcontrib>Polosa, M.</creatorcontrib><creatorcontrib>Sessa, M.</creatorcontrib><creatorcontrib>Conti Nibali, M.</creatorcontrib><creatorcontrib>Di Gennaro, G.</creatorcontrib><creatorcontrib>Gigli, G. L.</creatorcontrib><creatorcontrib>Pisanello, A.</creatorcontrib><creatorcontrib>Cavallieri, F.</creatorcontrib><creatorcontrib>Rudà, R.</creatorcontrib><title>Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients.
Methods
We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).
Results
Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice.
In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI).
Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months.
Side effects were mainly mild (grade 1–2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence.
Conclusions
This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.</description><subject>Acetamides</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - complications</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain tumors</subject><subject>Clinical Study</subject><subject>Cognition</subject><subject>Convulsions & seizures</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Epilepsies, Partial - complications</subject><subject>Epilepsies, Partial - drug therapy</subject><subject>Epilepsy</subject><subject>Epilepsy - complications</subject><subject>Epilepsy - etiology</subject><subject>Humans</subject><subject>Lacosamide - therapeutic use</subject><subject>Magnetic resonance imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Quality of Life</subject><subject>Retrospective Studies</subject><subject>Seizures</subject><subject>Seizures - drug therapy</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUuLFTEQhYMoznX0D7iQgJtxEU1SeXTc6TDqwAVBRnAXcrurtYfuTpukhf735npHBReuTh5fnariEPJU8JeCc_sqC8ENZ1xKxsG5hpl7ZCe0BWbBwn2y48JYpp36ckYe5XzLOVcWxENyBhqctdrtyLYPbcxhGjqkw0ynOMfyDVNYtuP17c2nK3pxSKGeyzrFxBKOoWBHcRlGXPL24jVNmNexZNqnONEw0-sSxqHqVF-HFueCqTIlxbxgW4YfSHNZu-0xedCHMeOTOz0nn99d3Vx-YPuP768v3-xZqxwvTCmADlpuQjAHJ8H14AA02oOoi1cBBZzLgG2DKJXRFlXQQaPqO-l6hHNycfJdUvy-Yi5-GnKL4xhmjGv20igntWkaWdHn_6C3cU1zna5S2jUVE0dKnqi2rpQT9n5JwxTS5gX3x2D8KRhf5_O_gvGmFj27s14PE3Z_Sn4nUQE4Abl-zV8x_e39H9ufAdiZzA</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Mo, F.</creator><creator>Meletti, S.</creator><creator>Belcastro, V.</creator><creator>Quadri, S.</creator><creator>Napolitano, M.</creator><creator>Bello, L.</creator><creator>Dainese, F.</creator><creator>Scarpelli, M.</creator><creator>Florindo, I.</creator><creator>Mascia, A.</creator><creator>Pauletto, G.</creator><creator>Bruno, F.</creator><creator>Pellerino, A.</creator><creator>Giovannini, G.</creator><creator>Polosa, M.</creator><creator>Sessa, M.</creator><creator>Conti Nibali, M.</creator><creator>Di Gennaro, G.</creator><creator>Gigli, G. L.</creator><creator>Pisanello, A.</creator><creator>Cavallieri, F.</creator><creator>Rudà, R.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8469-7567</orcidid></search><sort><creationdate>20220501</creationdate><title>Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study</title><author>Mo, F. ; Meletti, S. ; Belcastro, V. ; Quadri, S. ; Napolitano, M. ; Bello, L. ; Dainese, F. ; Scarpelli, M. ; Florindo, I. ; Mascia, A. ; Pauletto, G. ; Bruno, F. ; Pellerino, A. ; Giovannini, G. ; Polosa, M. ; Sessa, M. ; Conti Nibali, M. ; Di Gennaro, G. ; Gigli, G. L. ; Pisanello, A. ; Cavallieri, F. ; Rudà, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-4433d3c06aa6b9239f39335e7b1022e7b343002aec8ee24657e4a5a5e4fd29fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acetamides</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - complications</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain tumors</topic><topic>Clinical Study</topic><topic>Cognition</topic><topic>Convulsions & seizures</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Epilepsies, Partial - complications</topic><topic>Epilepsies, Partial - drug therapy</topic><topic>Epilepsy</topic><topic>Epilepsy - complications</topic><topic>Epilepsy - etiology</topic><topic>Humans</topic><topic>Lacosamide - therapeutic use</topic><topic>Magnetic resonance imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Quality of Life</topic><topic>Retrospective Studies</topic><topic>Seizures</topic><topic>Seizures - drug therapy</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mo, F.</creatorcontrib><creatorcontrib>Meletti, S.</creatorcontrib><creatorcontrib>Belcastro, V.</creatorcontrib><creatorcontrib>Quadri, S.</creatorcontrib><creatorcontrib>Napolitano, M.</creatorcontrib><creatorcontrib>Bello, L.</creatorcontrib><creatorcontrib>Dainese, F.</creatorcontrib><creatorcontrib>Scarpelli, M.</creatorcontrib><creatorcontrib>Florindo, I.</creatorcontrib><creatorcontrib>Mascia, A.</creatorcontrib><creatorcontrib>Pauletto, G.</creatorcontrib><creatorcontrib>Bruno, F.</creatorcontrib><creatorcontrib>Pellerino, A.</creatorcontrib><creatorcontrib>Giovannini, G.</creatorcontrib><creatorcontrib>Polosa, M.</creatorcontrib><creatorcontrib>Sessa, M.</creatorcontrib><creatorcontrib>Conti Nibali, M.</creatorcontrib><creatorcontrib>Di Gennaro, G.</creatorcontrib><creatorcontrib>Gigli, G. L.</creatorcontrib><creatorcontrib>Pisanello, A.</creatorcontrib><creatorcontrib>Cavallieri, F.</creatorcontrib><creatorcontrib>Rudà, R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mo, F.</au><au>Meletti, S.</au><au>Belcastro, V.</au><au>Quadri, S.</au><au>Napolitano, M.</au><au>Bello, L.</au><au>Dainese, F.</au><au>Scarpelli, M.</au><au>Florindo, I.</au><au>Mascia, A.</au><au>Pauletto, G.</au><au>Bruno, F.</au><au>Pellerino, A.</au><au>Giovannini, G.</au><au>Polosa, M.</au><au>Sessa, M.</au><au>Conti Nibali, M.</au><au>Di Gennaro, G.</au><au>Gigli, G. L.</au><au>Pisanello, A.</au><au>Cavallieri, F.</au><au>Rudà, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>157</volume><issue>3</issue><spage>551</spage><epage>559</epage><pages>551-559</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose
Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients.
Methods
We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).
Results
Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice.
In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI).
Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months.
Side effects were mainly mild (grade 1–2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence.
Conclusions
This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35397759</pmid><doi>10.1007/s11060-022-03998-6</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8469-7567</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2022-05, Vol.157 (3), p.551-559 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2649256882 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Acetamides Anticonvulsants - therapeutic use Brain cancer Brain Neoplasms - complications Brain Neoplasms - drug therapy Brain tumors Clinical Study Cognition Convulsions & seizures Drug-Related Side Effects and Adverse Reactions Epilepsies, Partial - complications Epilepsies, Partial - drug therapy Epilepsy Epilepsy - complications Epilepsy - etiology Humans Lacosamide - therapeutic use Magnetic resonance imaging Medicine Medicine & Public Health Multivariate analysis Neurology Oncology Patients Quality of Life Retrospective Studies Seizures Seizures - drug therapy Side effects Treatment Outcome |
| title | Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T10%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lacosamide%20in%20monotherapy%20in%20BTRE%20(brain%20tumor-related%20epilepsy):%20results%20from%20an%20Italian%20multicenter%20retrospective%20study&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Mo,%20F.&rft.date=2022-05-01&rft.volume=157&rft.issue=3&rft.spage=551&rft.epage=559&rft.pages=551-559&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-022-03998-6&rft_dat=%3Cproquest_cross%3E2649256882%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2659825612&rft_id=info:pmid/35397759&rfr_iscdi=true |